Baricitinib
Baricitinib is a pharmaceutical drug with 111 clinical trials. Currently 26 active trials ongoing. Historical success rate of 87.1%.
Success Metrics
Based on 54 completed trials
Phase Distribution
Phase Distribution
20
Early Stage
37
Mid Stage
45
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
83.1%
54 of 65 finished
16.9%
11 ended early
26
trials recruiting
111
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis
Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders
Clinical Trials (111)
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis
Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
A Study of Baricitinib in Participants With Rheumatoid Arthritis
Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial
TPO-RA Plus Baricitinib vs. TPO-RA for ITP
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
Baricitinib in Patients With Relapsing or naïve Dermatomyositis
Inflammation and Depression in People With HIV
JAK Signaling in Depression and Cognition in Male Football Players
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 111